Abstract: A method for separating oil-water two-phase NMR signals by using dynamic nuclear polarization comprising: using a combination of a non-selective free radical and a selective relaxation reagent to selectively enhance an NMR signal of an oil phase or a water phase, the relaxation reagent being capable of selectively suppressing dynamic polarization enhancement of the water phase or oil phase, thus achieving the polarization enhancement of a single fluid phase in the mixed fluid phases and realizing separation of the two-phase signals; or using a selective free radical to selectively enhance the NMR signal of the oil phase or the water phase, thus achieving the polarization enhancement of a single fluid phase in the mixed fluid phases and realizing separation of the oil-water two-phase NMR signals. The method is simple and easy to operate, has a short test time, and can efficiently separate NMR signals of oil and water phases.

Abstract: IGF1R biomarkers useful in a method for identifying and monitoring a mammal that will respond therapeutically to a method of treating cancer comprising administering an IGF1R modulator, wherein the method comprises (a) exposing the mammal to the IGF1R modulator and (b) measuring in the mammal the level of the at least one biomarker, wherein a difference in the level of the at least one biomarker measured in (b) compared to the level of the biomarker in a mammal that has not been exposed to the IGF1R modulator indicates that the mammal will respond therapeutically to the method of treating cancer and (c) wherein the level of the biomarker in a mammal after exposure to a IGF1R modulator indicates that the mammal has responded therapeutically to the method of treating cancer.

Abstract: IGF1R biomarkers useful in a method for identifying and monitoring a mammal that will respond therapeutically to a method of treating cancer comprising administering an IGF1R modulator, wherein the method comprises (a) exposing the mammal to the IGF1R modulator and (b) measuring in the mammal the level of the at least one biomarker, wherein a difference in the level of the at least one biomarker measured in (b) compared to the level of the biomarker in a mammal that has not been exposed to the IGF1R modulator indicates that the mammal will respond therapeutically to the method of treating cancer and (c) wherein the level of the biomarker in a mammal after exposure to a IGF1R modulator indicates that the mammal has responded therapeutically to the method of treating cancer.